# A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

> **NCT04346888** · PHASE2 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** HBM9161 Injection (680mg and 340 mg)
- **DRUG:** Placebos
- **DRUG:** HBM9161 Injection (340 mg)

## Key facts

- **NCT ID:** NCT04346888
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-23
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346888, "A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04346888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*